Press Release Archive
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc.
- Building on Pfizer’s longstanding commitment to fight infectious diseases, grants will help address urgent needs of U.S.
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc.
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced the election of Dr. Susan Desmond-Hellmann to its Board of Directors, effective immediately. Dr. Desmond-Hellmann, age 62, was also appointed to the Governance & Sustainability Committee and the Science and Technology Committee of Pfizer’s Board.
Three leading biopharmaceutical companies have announced programs enabling employees with medical and laboratory expertise to volunteer their services to local healthcare systems and those hardest hit by COVID-19.
- First in the industry sustainability bond provides opportunities to invest in projects supporting environmental sustainability and health of vulnerable populations
- Supports United Nations Sustainable Development Goals (SDGs)
- Due to global impact of COVID-19 pandemic, transaction now expected to close in the second half of 2020 and Mylan’s EGM moved to June 30 -
EUCRISA is the first and only 100% steroid-free, topical prescription medication approved for patients as young as 3 months of age in the United States
20-valent pneumococcal conjugate vaccine demonstrated comparable safety and immunogenicity profile to licensed pneumococcal vaccines
JADE COMPARE trial met all co-primary endpoints
Study included dupilumab in active control arm
Safety profile for abrocitinib consistent with previous studies
Pfizer Inc. (NYSE: PFE) announced today that given the unique circumstances of the COVID-19 pandemic and Pfizer’s responsibility to prioritize the health and safety of colleagues and invited guests, the company will reschedule its planned March 31, 2020 Investor Day for a later date.
At this point, there isn’t a timetable for rescheduling the event and Pfizer will work within the context of appropriate guidance from health authorities to determine a future date.
About Pfizer: Breakthroughs That Change Patients’ Lives
Pfizer Inc. (NYSE:PFE) today announced top-line results from one of its Phase 3 studies (NCT03760146), which evaluated the safety and immunogenicity of its 20-valent pneumococcal conjugate vaccine (20vPnC) candidate in adults 18 years of age or older not previously vaccinated against pneumococcal disease.
Pfizer Inc. (NYSE:PFE) announced today that JADE COMPARE (B7451029) met its co-primary efficacy endpoints. The Phase 3 study evaluated the safety and efficacy of abrocitinib, an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor, in adults with moderate to severe atopic dermatitis who were also on background topical therapy. The study also included an active control arm, dupilumab, a biologic treatment administered by subcutaneous injection, compared with placebo.
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, April 28, 2020.
Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, April 28, 2020. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2020 Performance Report, to be issued that morning.
Companies will jointly develop BioNTech’s mRNA-based vaccine candidate BNT162 to prevent COVID-19 infection
Collaboration aims to accelerate global development of BNT162, leveraging expertise and resources of both companies
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the companies have agreed to a letter of intent regarding the co-development and distribution (excluding China) of a potential mRNA-based coronavirus vaccine aimed at preventing COVID-19 infection. The companies have executed a Material Transfer and Collaboration Agreement to enable the parties to immediately start working together.
Chairman and CEO Albert Bourla Calls on Biopharma Industry to Collaborate on Combatting the Global Pandemic
NEW YORK--(BUSINESS WIRE)-- Pfizer today issued a five-point plan calling on the biopharmaceutical industry to join the company in committing to unprecedented collaboration to combat COVID-19.
Pfizer today issued a five-point plan calling on the biopharmaceutical industry to join the company in committing to unprecedented collaboration to combat COVID-19.
Dr. Albert Bourla, Chairman and CEO, made the following statement:
Rockland, MA and New York, US, March 13, 2020 – EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced an update from the Phase III JAVELIN Head and Neck 100 study evaluating avelumab in addition to chemoradiotherapy (CRT) versus standard-of-care CRT in patients with untreated locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).
Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.